Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

IgA vasculitis (Henoch-Schönlein purpura) in children: initial tests and renal monitoring

Paediatrics · Known disease · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: 3 to 27 cases per 100 000 children a year; kidney involvement in 20 to 54% of children [1]

At diagnosis: initial tests

Laboratory tests

Urine tests (first morning urine)

Detailed explanation and international comparison (in French): read it in English (machine translation)

No renal involvement at onset: monthly monitoring for 6 months

Every month for at least 6 months, even if the urine remains normal

Detailed explanation and international comparison (in French): read it in English (machine translation)

IgA vasculitis nephritis: follow-up shared with the paediatric nephrologist

Every month for 6 months

Then every 3 months for 6 months, then every 6 months for at least 5 years

Then: once a year, for life

Detailed explanation and international comparison (in French): read it in English (machine translation)

Also consider

Sources (6)
  1. Vivarelli M, Samuel S, Coppo R, Barratt J, Bonilla-Felix M, Haffner D, et al. IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis. Pediatr Nephrol. 2025;40(2):533-69.
  2. Reamy BV, Servey JT, Williams PM. Henoch-Schönlein Purpura (IgA Vasculitis): Rapid Evidence Review. Am Fam Physician. 2020;102(4):229-233.
  3. The Royal Children's Hospital Melbourne. Clinical Practice Guidelines : IgA vasculitis. Guide approuvé par le Paediatric Improvement Collaborative (Victoria, Australie), dernière mise à jour août 2026.
  4. Oni L, Mulvaney S, Haigh G, et al. ; UK IgAV Clinical Practice Guideline Working Group. UK Kidney Association Clinical Practice Guidelines for the Initial Management of IgA vasculitis (Henoch Schönlein Purpura) in children and young people. Version finale de décembre 2022 (révision prévue en décembre 2027).
  5. Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):S1-S71.
  6. Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis — the SHARE initiative. Rheumatology (Oxford). 2019;58(9):1607-1616.